CRHR1 Antibody

What is CRHR1 and why are antibodies against it important for research?

CRHR1 (Corticotropin Releasing Hormone Receptor 1) is a G protein-coupled receptor that exhibits high affinity for corticotropin-releasing hormone (CRH) and urocortin (UCN) but low affinity for UCN2 and no affinity for UCN3 . It plays a critical role in the body's stress response system by activating adenylyl cyclase when bound to its ligands.

CRHR1 antibodies are essential research tools because:

• They enable visualization and quantification of CRHR1 expression in various tissues

• They help establish relationships between CRHR1 expression and pathological conditions

• They allow researchers to study the role of CRHR1 in stress-related disorders, emotional adaptation, and various cancers

• They facilitate investigation of CRHR1-mediated signaling pathways in diverse physiological processes

CRHR1 is particularly important in neuroscience research as it is widely distributed throughout the brain and critically controls behavioral adaptation to stress, with causal links to emotional disorders .

What are the primary applications for CRHR1 antibodies in research?

CRHR1 antibodies are versatile research tools with multiple validated applications:

The specificity of application depends on the particular antibody being used. For example, product 20967-1-AP targets CRHR1 in WB, IF, and ELISA applications and shows reactivity with human samples .

What types of CRHR1 antibodies are available for research use?

Several types of CRHR1 antibodies are available, varying in host species, clonality, and targeting epitopes:

The choice depends on experimental needs. For example:

• The goat anti-CRHR1 polyclonal antibody recognizes the N-terminus (amino acids 107-117), which resides in the first extracellular domain and is distinct from the CRHR2 peptide sequence

• Rabbit polyclonal antibodies may target different epitopes, including the N-terminus, C-terminus, or internal regions

How does CRHR1 expression correlate with disease progression and prognosis in cancer research?

Research has demonstrated significant associations between CRHR1 expression and cancer prognosis:

In endometrial carcinoma:

This relationship is visualized in survival analyses showing that CRHR1-positive patients had significantly worse outcomes compared to CRHR1-negative patients. In contrast, CRHR2 status was marginally associated with better clinical outcomes (p = 0.093) .

Additionally, in other malignancies:

• CRHR1 immunoreactivity has been detected in adrenal cortical (23%), breast (31%), ovarian (64%), and endometrial (92%) carcinomas

• In ovarian carcinoma, CRH increases the expression of Fas ligand through CRHR1, potentially affecting immune evasion

• In endometrial carcinoma, CRH stimulation enhanced migration and invasiveness through increased levels of matrix metalloprotease 2 and 9 proteins

What methods are most effective for validating CRHR1 antibody specificity in experimental studies?

Validating CRHR1 antibody specificity is crucial for reliable research outcomes. Based on multiple studies, the following complementary approaches are recommended:

• Immunocytochemistry (ICC) with transgenic reporter systems:

  • Use transgenic Flp reporter mice crossed with CRHR1-FlpO mice to determine if antibody staining patterns match genetic reporter expression

  • Compare antibody staining patterns with the anatomical distribution of CRHR1 established in literature

• Multiple antibody validation:

  • Compare staining patterns using antibodies targeting different epitopes of CRHR1

  • For example, compare N-terminus targeting antibodies with C-terminus targeting antibodies to confirm consistency

• Western blot verification:

  • Verify that immunoblot bands match the calculated molecular weight (48 kDa) and observed molecular weight range (46-55 kDa)

  • Test multiple tissue types to confirm consistent reactivity patterns

• Negative and positive controls:

  • Use established positive control tissues (e.g., placental tissue for CRH and UCN, thyroid cancer tissues for CRHR1)

  • Include negative controls by omitting primary antibody incubation

  • Use knockout tissue or RNA interference where available

How should researchers interpret variations in CRHR1 immunoreactivity across different tissue types?

Interpreting variations in CRHR1 immunoreactivity requires understanding tissue-specific expression patterns and using appropriate quantification methods:

• Quantification methods:

  • The H-score system is widely used: H-score = [1 × (% cells 1+) + 2 × (% cells 2+) + 3 × (% cells 3+)], with values from 0 to 300

  • Statistical comparisons between tissue types should use non-parametric tests such as Kruskal-Wallis or Mann-Whitney U tests for H-score comparisons

• Tissue-specific patterns:

  • CRHR1 is highly expressed in the brain, particularly in the cerebral cortex

  • CRHR1 is also notably expressed in the pituitary gland and testis

  • In vulvar disease progression, CRHR1 expression increases significantly from benign to malignant tissues:

    • Lichen samples showed mean H-score of 0

    • VIN (Vulvar Intraepithelial Neoplasia) samples showed mean H-score of 0.8

    • VSCC (Vulvar Squamous Cell Carcinoma) samples showed mean H-score of 6.5 (p < 0.001 compared to lichen)

• Cellular localization:

  • CRHR1 typically shows cytoplasmic staining patterns

  • Nuclear staining may indicate non-specific binding or alternative isoforms

What are the optimal protocols for using CRHR1 antibodies in immunohistochemistry and immunofluorescence?

For optimal results with CRHR1 antibodies in IHC and IF applications:

Immunohistochemistry Protocol:

• Tissue preparation:

  • Use formalin-fixed, paraffin-embedded (FFPE) sections

  • Include appropriate positive controls (thyroid cancer tissues for CRHR1)

  • Include negative controls by omitting primary antibody

• Antigen retrieval:

  • Heat-induced epitope retrieval is typically recommended

• Blocking and antibody incubation:

  • Block with 5% normal serum derived from the same host species as secondary antibodies (e.g., rabbit or donkey)

  • Use recommended dilutions (typically 1:100-1:1000 for IHC-P)

  • For CRHR1 specifically, incubate with primary antibody at +4°C for 72 hours for optimal results

Immunofluorescence Protocol:

• For free-floating tissue sections:

  • Wash and permeabilize in 0.01 M PBS containing 0.3% Triton X-100 (PBS-T) for 30 min

  • Treat with 0.3% H₂O₂ in PBS-T for 30 min followed by washing

  • Block with 5% normal serum

  • Incubate with primary antibody (e.g., Goat anti-CRHR1 at 1:2,000) at +4°C for 72 hours

  • Use appropriate fluorophore-conjugated secondary antibodies, such as:

    • Cy3 AffiniPure Rabbit Anti-Goat (1:500)

    • Donkey anti-Goat Alexa Fluor 488 (concentration varies)

• For cultured cells:

  • Fix cells in 37% formaldehyde solution

  • Permeabilize with appropriate detergent

  • Follow similar blocking and antibody incubation steps as above

What considerations are important when selecting a CRHR1 antibody for specific research applications?

When selecting CRHR1 antibodies for research, consider these critical factors:

• Target epitope and specificity:

  • N-terminal targeting antibodies (amino acids 107-117) recognize the extracellular domain and can distinguish between CRHR1 and CRHR2

  • Choose epitopes based on experimental needs (e.g., extracellular domains for live cell applications)

• Host species compatibility:

  • Consider potential cross-reactivity with secondary detection systems

  • Plan secondary antibody compatibility with other primary antibodies for co-staining

• Validated applications:

  • Verify the antibody has been validated for your specific application

  • Review published literature using the specific antibody clone/catalog number

• Sample reactivity:

  • Match antibody reactivity (human, mouse, rat) to your experimental model

  • Consider cross-species reactivity when working with non-human models

• Clonality considerations:

  • Polyclonal antibodies offer higher sensitivity but may have more batch-to-batch variation

  • Most common CRHR1 antibodies are polyclonal due to technical challenges with monoclonal development

How should CRHR1 antibody data be quantified and statistically analyzed in comparative studies?

• Quantification systems:

  • For immunohistochemistry: Use H-score system [1 × (% cells 1+) + 2 × (% cells 2+) + 3 × (% cells 3+)]

  • For Western blot: Normalize band intensity to housekeeping proteins

  • For qPCR validation: Use the 2^(-ΔCT) calculation method where ΔCT = (CT-target gene − CT-GAPDH)

• Statistical approaches for different data types:

  • For comparing H-scores across multiple groups: Use non-parametric Kruskal-Wallis test followed by Mann-Whitney U test for pairwise comparisons

  • For survival analysis: Apply Kaplan-Meier plots with log-rank tests

  • For comparing means across multiple groups: Use one-way ANOVA with appropriate post-hoc tests (Newman-Keuls)

  • For two-group comparisons: Use two-tailed Student's t-tests for normally distributed data

• Statistical significance thresholds:

  • Most studies use p < 0.05 as the threshold for statistical significance

  • For multiple comparisons, consider Bonferroni corrections

What are common challenges when working with CRHR1 antibodies and how can they be addressed?

Researchers commonly encounter these challenges when working with CRHR1 antibodies:

• Non-specific binding:

  • Problem: Background staining obscuring specific signals

  • Solution: Optimize blocking (use 5% normal serum from secondary antibody host species)

  • Solution: Titrate antibody concentrations to find optimal dilution (start with manufacturer recommendations and adjust)

• Weak or absent signal:

  • Problem: Low target protein abundance

  • Solution: Extended primary antibody incubation (72 hours at +4°C for CRHR1)

  • Solution: Signal amplification techniques (e.g., ABC method for IHC)

  • Solution: Consider alternative antibody targeting different epitope

• Inconsistent results across experiments:

  • Problem: Batch-to-batch variation in polyclonal antibodies

  • Solution: Purchase larger quantities of single lot when possible

  • Solution: Always include positive control samples

  • Solution: Validate each new batch with known positive samples

• Cross-reactivity with CRHR2:

  • Problem: Similar structure between receptor subtypes

  • Solution: Use N-terminal targeting antibodies (amino acids 107-117) which target regions distinct from CRHR2

  • Solution: Validate specificity using tissues with known differential expression of CRHR1 vs CRHR2

How can researchers effectively pair CRHR1 antibodies with other molecular techniques to strengthen experimental findings?

Integrating multiple techniques with CRHR1 antibody studies enhances research validity:

• Chromatin Immunoprecipitation (ChIP) integration:

  • Use CRHR1 antibodies to study downstream transcription factor activation

  • Example: CRH treatment of cells followed by ChIP with anti-CREB antibody to study VEGF promoter binding

  • Protocol: Fix cells, lyse, sonicate chromatin, immunoprecipitate with relevant antibodies, extract and amplify DNA by PCR

• Genetic validation approaches:

  • Use CRHR1-FlpO transgenic mice with Flp-dependent reporter systems

  • Inject Flp-dependent adeno-associated viruses (AAVs) into target brain regions

  • Compare Flp-dependent expression with CRHR1 antibody staining

• Functional assays combined with immunodetection:

  • Pair receptor expression studies with functional calcium imaging

  • Combine CRHR1 antibody detection with phospho-specific antibodies to monitor downstream signaling

  • Correlate CRHR1 expression with physiological readouts in the same samples

• Transcriptomic correlation:

  • Validate antibody findings with RT-qPCR for CRHR1 mRNA

  • Use relative quantification with 2^(-ΔCT) calculation method

  • Compare protein expression patterns with transcriptomic data from the same tissues

How do different CRHR1 isoforms affect antibody selection and experimental design?

The existence of multiple CRHR1 isoforms has important implications for antibody-based research:

• Isoform considerations:

  • Human CRHR1 has at least 5 identified isoforms with variable extracellular and transmembrane domains

  • The canonical isoform has 444 amino acid residues and a protein mass of 50.7 kilodaltons

  • Observed molecular weight ranges from 46-55 kDa in Western blots

• Epitope selection strategies:

  • Target shared regions to detect all isoforms

  • Target unique regions to discriminate between specific isoforms

  • Consider epitope accessibility in different experimental conditions (native vs. denatured)

• Isoform-specific expression patterns:

  • Different tissues may express different isoform profiles

  • Brain regions show differential expression of CRHR1 isoforms

  • Consider tissue-specific isoform expression when interpreting results

• Functional implications:

  • Isoforms may have different ligand binding properties and signaling capabilities

  • When studying functional outcomes, consider which isoforms your antibody detects

  • Correlate antibody findings with functional assays specific to the isoforms of interest